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ABSTRACT 
 
 Fragile X Syndrome (FXS) is a disorder caused by a congenital mutation of the 
FMR1 gene on the X chromosome.  FXS is associated with moderate to severe 
intellectual disability and is one known cause of autism spectrum disorders.  There are no 
approved medications to treat FXS symptoms.  In 2013, Seaside Therapeutics completed 
two Phase 3 studies of an investigational medication, STX209, for treatment of social 
withdrawal in FXS.  Efficacy results for these studies were not positive.  
Clinical trials of psychoactive drugs often fail to show a statistical difference from 
placebo controls and a robust response to placebo is often cited as a reason for the failure.  
Retrospective studies of baseline variables in clinical trials have identified characteristics 
that were associated with an increased likelihood of responding to placebo.  Such 
information is valuable for the design of future clinical trials and no such studies have 
been conducted in FXS.  This study was a post-hoc analysis of data from Seaside 
Therapeutics’ Phase 3 clinical trials in FXS.  Baseline variables for subjects receiving 
placebo were pooled for analysis.   To determine if a subject responded to placebo, the 
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parent-rated ABC-SA and the ABC-IR were used.  Clinician-rated assessments, including 
the CGI-S and CGI-I, were examined as well.  Two-sample t-testing, one-way ANOVA 
testing, and correlation coefficients were calculated to compare the responses of subjects 
with different baseline characteristics.  General linear regression modeling was used to 
determine if there were multiple baseline variables that could predict placebo response.   
Logistic regression modeling was used to determine if the baseline variables could 
predict whether a subject had a higher chance of being a treatment responder. 
A total of 287 subjects were randomized and completed the Phase 3 studies.  
Analyses for this study were conducted in a subgroup containing 106 subjects who 
received placebo.  76% improved during the study on the ABC-SA, indicating that there 
was a strong placebo effect on the study.  None of the dichotomous baseline variables 
were associated with statistically significant differences in ABC-SA, ABC-IR, CGI-S, or 
CGI-I scores.   Placebo-treated subjects in the 209FX302 study who were taking 
antipsychotics improved less on the CGI-S than those not on those medications.  A 
similar pattern was observed on the ABC-IR and ABC-SA.  Other categorical baseline 
variables were tested and there was no difference in the mean changes.  The CGI-S score 
at baseline appeared to predict a statistically significant difference in the ABC-IR as more 
severe subjects were more likely to show a larger change in the ABC-IR.  Similar, 
although not statistically significant results were seen with ABC-SA, CGI-I, and CGI-S 
changes, in that more severe subjects had greater responses to placebo.   
ABC-IR score changes were correlated independently with each of the ABC-C 
subscales but also with parental distress, CGI-S, and VAS-Anxiety.  Only one variable, 
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the ABC-IR at baseline, was significantly correlated with the ABC-SA score change, the 
rest of the variables were not significant.  A multiple linear regression model predicting 
placebo response for the ABC-SA included only the baseline ABC-SA score.  When the 
studies were modeled separately, the 209FX302 model contained additional variables 
including gender, antipsychotic use, and ABC-stereotypy scores.  For the ABC-IR change 
model, the highest correlation coefficient was found in the 209FX301 study with ABC-
IR, gender, Vineland-communication, maternal FMR1 status, and ABC-SL included in 
the model.  70% of the placebo treated subjects improved on the ABC-SA by at least 
25%.  Placebo responders were less frequently observed in clinician-rated assessments 
such as the CGI-I and CGI-S.   In logistic regression models, for the ABC-IR response, a 
higher score on the hyperactivity subscale of the ABC-C was predictive of a lower 
placebo response.  The CGI-S model was statistically significant and included the 
subject’s age, race and ABC-IS score.  The ABC-SA response could be modelled only in 
the 209FX302 study with gender and ADHD medication use remaining in the model.   
Also in the 209FX302 study, subjects were far less likely to be a responder on the ABC-
IR or a total responder, if they were taking antipsychotic medications.    
Results of this study indicate that the ABC-SA is not recommended in future trials 
in the FXS patient population.  Future trials should also allow ADHD and antipsychotic 
medication use as they were associated with a lower placebo response in some analyses.   
In addition, due to their inclusion in regression models, future studies should consider 
baseline variables such as parental stress and Vineland scores, and when designing study 
eligibility criteria or stratification variables. 
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BACKGROUND:  
 
Fragile X Syndrome (FXS), first known as Martin-Bell Syndrome, was first described in 
1943 after examining several adult males with mental ages of 2-4 years. Interviews with 
the patients’ cognitively normal mothers revealed a pedigree that suggested the disorder 
was due to a sex-linked recessive gene (Martin & Bell, 1943).   FXS is associated with 
moderate to severe intellectual disability and is the most common inherited cause of 
intellectual disability.  Patients often cannot live independently and require a lifetime of 
support.  FXS is also closely associated with Autism Spectrum Disorder (ASD) (Loesch 
et al., 2007).   
Symptoms of FXS 
Patients with FXS often perform poorly on measures of memory, attention, and executive 
function.  Males with FXS typically display a moderate to severe level of intellectual 
disability.  In females, the level of intellectual disability is more variable due to the 
presence of a “healthy” allele.  Behavioral abnormalities commonly observed are hand-
flapping, gaze aversion, repetitive movements, or echolalia, or hypersensitivity to noise 
or touch (Hagerman & Berry-Kravis, 2009).  Shy or socially withdrawn behavior is 
common, so are abnormal social behaviors.  One report of FXS patients noted unusual 
greeting behaviors in which patients with FXS would avoid eye contact and turn their 
body away from the person they are greeting, even while voluntarily shaking hands 
(Wolff, Gardner, Paccla, & Lappen, 1989).  Psychologically, patients often experience 
high anxiety, inattention, impulsivity, irritability, mood instability, inflexibility, and 
difficulty making transitions.  Neurological symptoms including seizures occur in 10-
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40% of FXS patients.  The average Intelligence Quotient (IQ) for boys with FXS is 45, 
for girls it is 76, closer to the normal range of 90-109 but still well below average (Hall et 
al., 2010).  This cognitive deficit does continue throughout the patients’ lifespan.  In adult 
males, 95% of males have an IQ below 70 and 10% have an IQ below 20.  50% of FXS 
adult females have an IQ less than 70 (Denman, 2012). 
There are physical features that are associated with FXS such as hyperextensible 
joints, poor posture, flat feet, prominent ears, large forehead, and elongated faces.  
Additional connective tissue abnormalities can result in mitral valve prolapse and 
macroorchidism.  The physical features associated with FXS are not uniform and roughly 
30% of children with FXS do not have these characteristics.  Some of the features 
become more pronounced in adulthood (Chonchaiya et al., 2009).  
Disease Etiology 
FXS develops when a congenital mutation of the Fragile X Mental Retardation Type 1 
(FMR1) gene at locus q27.3 on the X chromosome causes the silencing of the gene and 
prevents transcription of the Fragile X Mental Retardation Protein (FMRP).  An 
expansion of a more than 200 repeats of the trinucleotide repeat sequence (CGG) in the 
gene generally results in hypermethylation of the gene and prevents FMRP from being 
produced.  FMRP is a Ribonucleic Acid (RNA)-binding and transport protein that plays 
an inhibitory role in the regulation of protein synthesis in the brain.    Roughly one-third 
of all messenger RNA (mRNA) encoding pre- and post-synaptic proteins are targets of 
FMRP so it is likely involved in a number of signaling pathways (Wijetunge et al., 2013).  
In the absence of FRMP, cytoskeleton proteins in the hippocampus and amygdala are 
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over-expressed and dendrites connecting neurons appear disorganized and immature 
(Hagerman, 2008).  These brain regions are associated with memory and learning 
(hippocampus) and emotional response (amygdala).  Abnormalities in these regions could 
be a directly related to several of the cognitive and behavioral symptoms seen in FXS 
such as learning disabilities, anxiety, and emotional outbursts (Hooper et al., 2008).  The 
hypothalamus is also larger in FXS, which could be associated with enhanced cortisol 
release, which could be a cause of sleep disturbances often observed in FXS 
(Chonchanaiya, Schneider, & Hagerman, 2009). 
Incidence and Diagnosis  
FXS affects approximately 1 in 4,000 males and 1 in 6,000 females, or 90,000 people in 
the United States, making it an orphan disease.  The actual incidence may be higher but 
the screening test is not standard of care in any country but Israel, where prenatal 
screening for the disease is covered by insurance and routinely performed (Yaron Y, 
Musci T, & Cuckle H, 2013).   Polymerase Chain Reaction (PCR) and Southern Blot 
genetic tests can accurately identify the size of the FMR1 gene and can provide a 
molecular diagnosis, however, FXS has no obvious phenotype at birth, so genetic testing 
is usually only requested later in life as developmental delays become evident.   
The first indicators of FXS in children include lack of eye contact, difficulty 
interacting with others, socially abnormal behavior, poor eating habits, and aversion to 
being touched.  The average age of diagnosis in boys is 38 months with a 24-month lapse 
between the first concerns of the parent and diagnosis from a physician.  This delay in 
knowledge is often frustrating for parents of children with FXS; 31% of parents surveyed 
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gave birth to another child with FXS before knowing that their first child had the disorder 
(Bailey et al, 2003; Bailey D, Raspa M, Bishop, & Holiday D, 2009).  Since girls are 
generally less affected than boys, a female child is diagnosed on average six months later 
and often only after a male sibling fails to reach developmental milestones, is screened 
for the mutation, and receives a positive diagnosis for FXS (Bailey et al., 2003). 
Relationship with Autism Spectrum Disorders 
ASD is a group of heterogeneous developmental disabilities characterized by deficits in 
reciprocal communication and social function as well as poor cognitive flexibility which 
includes restricted interests, stereotypy, and repetitive behaviors.  The known prevalence 
of ASD has increased in recent years from 19 in 10,000 to as high as 1 in 150 people, 1 in 
110, and now ASD is thought to affect 1% of the population worldwide.  No single 
etiology has been identified.  A genetic component is surely part of the disorder and 
dozens of genetic mutations and polymorphisms have been associated with ASD.  Non-
genetic factors including prenatal and perinatal risk factors have also been theorized to be 
involved including maternal nutrition, parental age, and environmental toxins (Won, 
Mah, & Kim, 2013).  ASD can only be diagnosed via behavioral assessments whereas 
FXS can be definitively diagnosed using a variety of genetic tests (Chonchaiya et al, 
2009).   An estimated 2-7% of patients with ASD have an FMR1 mutation, making FXS 
making it the most common known genetic cause of ASD (Hagerman, 2008).  Commonly 
used assessments to diagnose ASD include: Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM-IV), Autism Diagnostic Observation Schedule (ADOS), 
and Autism Diagnostic Interview-Revised (ADI-R).  In a study of these assessments in 
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patients with a FXS diagnosis, 24% of the patients met the criteria for ASD on all three 
assessments (Hall et al., 2010).    
Patients with FXS often display social impairment, sensory hyper-arousal, 
aggression, gaze aversion, and repetitive vocalizations that appear similar to those of 
patients with ASD (Hall et al, 2010).  The caudate nucleus and amygdala have been 
shown to be larger than controls in both FXS and ASD, meaning there could be 
commonalities in the neuropathology.  Some of the proteins regulated by FMRP, such as 
neuroligin 3 and the SHANK protein are known to cause autism when mutated 
(Hagerman, 2008).   
Despite the similarities, there are important differences between the two disorders 
in that cognitive deficits are more common in FXS.  ASD includes Asperger’s Syndrome, 
in which patients are often highly intelligent but even patients with classic autism 
typically have an IQ higher than the average IQ in FXS patients.  In addition, the 
characteristic physical features of FXS are not found in most patients with ASD.  While 
social abnormalities are common in both disorders, patients with ASD exhibit more 
pronounced social withdrawal, whereas in FXS, core social deficits are more often 
manifested as abnormal speech or social anxiety or awkwardness.  One study noted that 
FXS patients exhibited less gaze avoidance with familiar people than with strangers but 
with ASD there was no difference.  Eye-tracking studies have shown a difference in that 
FXS patients focus on the mouths, instead of eyes of pictures or faces and patients with 
ASD are indifferent and tend not to look at faces at all (Hall et al., 2010).  While FXS 
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patients score highly on autism rating scales, they often clearly seek social interaction 
even though they seem unable to interact successfully (Denman, 2012).    
Carriers and Other FMR1 Disorders  
Mutations in the FMR1 gene are usually inherited and are passed onto the next 
generation in cumulative fashion.  The mutation’s penetrance increases as it passes from 
generation to generation and the CGG repeat region expands.  For instance, a 
phenotypically normal mother could have a FMR1 gene mutation with 50 CGG repeats 
and be a carrier of the mutation; her daughter might have an FMR1 gene with 120 CGG 
repeats and be a carrier as well; her grandson could have an FMR1 gene with 210 CGG 
repeats and be affected by FXS.  The range of CGG repeats (50-200) is known as the pre-
mutation range.  A female carrier could also have the full mutation (200+ CGG repeats) 
on one chromosome and still not have obvious FXS symptoms.  Both pre-mutation and 
full-mutation carriers produce a degree of FMRP, but not as much as normal controls and 
reduced FMRP has been associated with amygdala dysfunction (Hessl et al., 2011).   
  The prevalence of FMR1 pre-mutation carriers has been estimated to be as high 
as 1 in 113 females and 1 in 251 males.  As compared to controls, pre-mutation carriers 
have been shown to have reduced grey matter in the amygdala and hippocampus.  In one 
study, pre-mutation carriers scored lower on measures of reciprocal social behavior and 
communication than controls without any FMR1 mutation (Bourgeouis et al., 2009).  
Several studies have noted that these carriers often appear to function normally but are 
likely to display several psychiatric comorbidities such as recurring depressive episodes, 
anxiety disorder, and mild cognitive deficits, including social cognition and executive 
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function deficits.  The severity of these symptoms may be worse in full mutation carriers 
than in pre-mutation carriers (Cornish, et al., 2005).  The pre-mutation is even 
hypothesized to contribute to ASD in some cases through RNA toxicity.  In pre-mutation 
carriers, mRNA is often over-expressed and this could stimulate neuroimmune responses 
that mimic other causes of ASD.  In ex-vivo studies, neurons with the pre-mutation are 
also more vulnerable to cell death following oxidative stress and environmental toxicity 
(Hagerman & Hagerman, 2004).  
The FMR1 pre-mutation is also associated with two disorders known as Fragile X 
Tremor Ataxia Syndrome (FXTAS) and Fragile X Premature Ovarian Insufficiency 
(FXPOI).   In 20% of female pre-mutation carriers, menstruation will cease prior to 40 
years of age as compared to 1% of the general population and this condition is known as 
FXPOI (Oostra & Willemsen, 2009). Roughly 1 in 700 males have the pre-mutation and 
it can lead to a condition known as FXTAS.   FXTAS is similar in appearance to 
Parkinson’s disease as it is a multi-symptom, progressive, neurological disorder that 
includes tremors, ataxia, cognitive dementia, executive function deficits, and neuropathy.  
It is also estimated that 1 in 3,000 men older than 50 years of age in the general 
population will develop symptoms of FXTAS (Chonchaiya et al., 2009; Oostra & 
Willemsen, 2009). 
Current and Investigational Therapies 
There are no Food and Drug Administration (FDA)-approved medications for FXS.  
Several medications are prescribed off-label for the behavioral manifestations of the 
disorder and approximately 61% of males with FXS are taking at least one medication to 
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treat their behavioral symptoms.  Patients with FXS often are hyperactive and thus 
stimulants are the most frequently prescribed medications.  Stimulants are beneficial in 
reducing problem behaviors for 70-90% of FXS boys with symptoms of attention deficit 
and hyperactivity disorder (ADHD) and less effective for girls (Bailey, et al., 2012).  For 
irritable or aggressive patients, antipsychotics such as aripiprazole and risperidal are 
commonly administered.  Significant aggression or self-injurious behavior is present in 
approximately 20% of boys with FXS and tends to increase with age (Erickson, et al., 
2011).  These drugs are FDA-approved for irritability associated with ASD, but have not 
been studied in controlled trials of FXS patients.  Patients with FXS often experience 
sleep disturbances and thus melatonin is used often.  Selective Serotonin Reuptake 
Inhibitors (SSRIs) are often prescribed for anxiety-driven behaviors or repetitive 
behaviors.  There have not been large, controlled trials and studies to-date in SSRIs.  
Open-label trials have shown a benefit in a small percentage of patients and side effects 
related to psychomotor activation (anxiety, restlessness, or repetitive behaviors) are 
common.  Furthermore, treatment with SSRIs does not address the social abnormalities of 
FXS (Hagerman et al., 2009). 
Mitigating the most overt behavioral symptoms of FXS will certainly benefit 
patients and families, however recently research into the molecular picture of FXS has 
led to the possibility of developing a targeted treatment for FXS that could be disease-
modifying.  The FMR1 gene and FMRP structure are well-conserved across other 
species.  Animal models of FXS have been created that silence the FMR1 gene and thus 
mimic the principal molecular deficiency in humans with FXS.  These models express 
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behavioral and physiological characteristics that are analogous to FXS in humans.  For 
instance, FMR1 knockout mice show highly increased anxiety-driven behaviors such as 
marble-burying, decreased social interaction, and avoidance of open spaces.  The mice 
are also prone to audiogenic seizures and have abnormal dendritic spines in hippocampus 
neurons (Denman, 2009).   Research in animal models determined that these symptoms 
of FXS reflect excessive protein synthesis downstream of the metabotropic glutamate 5 
receptors (mGluR5) in the brain.  The excessive proteins lead to exaggerated long-term 
depression and disrupted neural plasticity.   Long-term depression is the opposing 
synaptic process to long-term potentiation and is critical to neuronal development.  Long-
term depression is important in the selective pruning of neuronal networks.  However, 
when exaggerated, long-term depression will result in the weakening of neuronal 
connections.  Therefore, it was hypothesized that antagonizing the mGluR5 receptor may 
normalize long-term depression in some regions of the brain and alleviate the symptoms 
of FXS (Dolen et al., 2007).  This was indeed the case in animal models and drugs 
inhibiting mGluR5 reversed the abnormal phenotypes seen in the FMR1 knockout 
models.   
mGluR5 receptor antagonists are now being studied in clinical research.  The first 
drug of this class examined in FXS was fenobam.  An open-label Phase 1 study was 
conducted and fenobam led to a 20% improvement in a neurophysiological marker of 
FXS called prepulse inhibition (Berry-Kravis, et al., 2009).   Another mGluR5 receptor 
antagonist, AFQ056 is being developed by Novartis and Phase 2 study of the drug did not 
show an effect overall on a parent-rated behavioral assessment, but a post-hoc analysis 
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revealed an effect in a sub-population of patients with full methylation of the FMR1 gene 
promoter (Levenga et al., 2011).  A third mGluR5 receptor antagonist is being developed 
by Roche Pharmaceuticals and Phase 2 study results are not yet available (Hagerman et 
al., 2009).    At least one drug is being studied in FXS that works via a slightly different 
mechanism.  Minocycline is an antibiotic that has been available since the 1970’s and has 
been shown to disrupt proteins that are responsible for creating immature dendritic 
spines.  Patients in these studies displayed improvements in measures of cognition, 
language, and behavior although the safety of long-term treatment of the drug has been 
questioned (Leigh et al., 2012).   
 The largest clinical trials in FXS to-date have evaluated the investigational drug 
STX209, also known as arbaclofen.  STX209 is a gamma-aminobutrytic acid type B 
receptor (GABA-B) agonist being developed by Seaside Therapeutics.  STX209 is the 
active enantiomer of racemic baclofen, a medication approved as Kemstro for the 
treatment of muscle spasticity.  STX209 has been shown to be more potent in animal 
models, and better tolerated in preliminary human studies than racemic baclofen 
(STX209 Investigator’s Brochure).   
GABA-B receptors play a crucial role in the brain as an inhibitory pathway.  
Animal models of FXS have shown a decrease in GABA receptors in several brain 
regions as compared to controls.  Furthermore, the same abnormal behavioral phenotypes  
in FMR1 knock-out mice that were corrected by mGluR5 antagonists can be corrected by 
STX209 (STX209 Investigator’s Brochure).  Two mechanisms of action for STX209 
have been proposed.  The first is that the excitation:inhibition balance in the brain is 
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abnormal in FXS as GABA-mediated inhibitory neurotransmission is deficient in FXS 
animal brains (Olmos-Serrano et al., 2010). This deficiency, which is particularly well-
studied in the amygdala of the FMR1 knockout mouse, serves as a specific substrate upon 
which STX209 may act to alleviate symptoms associated with social anxiety and 
emotional hyperarousal.  The second proposed mechanism is the same described above 
for mGluR5 receptors.  Activating presynaptic GABA-B receptors is known to decrease 
the amount of glutamate that is released into the synapse, and thus could indirectly inhibit 
the mGluR5 signaling pathway.   
Clinical Experience with STX209 
A small number of clinicians have used racemic baclofen off-label to treat patients with 
FXS. Initially, Seaside Therapeutics sponsored a retrospective chart review patients with 
FXS and idiopathic autism who were treated with racemic baclofen. In patients with 
FXS, racemic baclofen doses were titrated and maintained for a maximum duration of 4 
months and reported areas of improvement included increased class participation and 
decreased hyperactivity. In the patients with idiopathic autism, the reported 
improvements included better communication and social interaction, increased class 
participation, and decreased hyperactivity (STX209 Investigator’s Brochure). 
Seaside Therapeutics first evaluated STX209 in FXS patients in a Phase 2, 
randomized, placebo-controlled, cross-over study for the treatment of irritability in 
subjects with FXS.  Each treatment period was four weeks in duration.  The study did not 
show a statically significant improvement of the ABC-C irritability subscale (ABC-IR) 
while on STX209 as compared to placebo, but when a FXS-specific subscale for social 
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avoidance (ABC-SA) was used, there was a clear treatment effect as compared to 
placebo.  The evidence of an effect on sociability was strengthened when a subgroup of 
patients who scored higher than average on a measure of social withdrawal at baseline, 
showed statistically significant improvement on STX209 on nearly every efficacy 
endpoint.  Lastly, at the end of the study both clinicians and parents/caregivers were 
asked during which treatment period the subject displayed preferable behaviors and more 
people (2:1 ratio) in each group chose the period when STX209 was administered.  
STX209 appeared to be well tolerated with few adverse events, which were mostly mild 
headaches and sedation (Berry Kravis, et al., 2012). 
To continue the evaluation and development of STX209 for the treatment of FXS, 
two Phase 3 studies were conducted by Seaside Therapeutics.  Specifics of the study 
designs are described in the Materials and Methods section.  The protocol titles and a 
summary of the study results are described below: 
209FX301: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social 
Function in Adolescents and Adults with Fragile X Syndrome 
 
   This protocol was a randomized clinical trial to evaluate the safety and efficacy 
of STX209 in subjects 12-50 years of age for the treatment of social function 
abnormalities in FXS.  125 subjects were randomized to receive either STX209 or 
placebo and physicians could titrate the dose of study medication to find the optimal dose 
for each subject.  Twelve subjects did not complete the protocol.  Reasons for early 
discontinuation included: adverse event (5 on STX209, 1 on placebo), lack of efficacy (2 
on STX209), protocol violation (1 on STX209), and lost-to-follow-up (2 on STX209, 1 
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on placebo).  Safety results demonstrated that STX209 was well tolerated, the most 
common adverse events in the study were headaches (15% vs. 10% on placebo), 
vomiting (15% vs. 5% on placebo), irritability (10% vs. 6% on placebo), and nausea 
(10% vs. 2% on placebo).  Efficacy results for the study were not positive.  In the intent-
to-treat population (ITT), the primary efficacy variable, ABC-SA, improved by 
approximately 30% in the STX209 treatment group, but the same magnitude of change 
was seen in the placebo group, resulting in a highly statistically insignificant difference 
(p=0.974).  Results in the per-protocol (PP) population were similar.  Secondary and 
exploratory efficacy endpoints each showed improvement on each measurement, but 
similar improvements in the placebo group were seen and none of the differences were 
statistically significant.  Only one measurement, a global clinician assessment of 
behavioral severity, CGI-S, improved more on STX209 as compared to placebo and 
approached statistical significance (p=0.06). 
209FX302: A Randomized, Double-Blind, Placebo-Controlled Fixed-Dose Study of the 
Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment 
of Social Function in Children with Fragile X Syndrome 
 
This protocol was a randomized, fixed-dose trial to evaluate the safety and 
efficacy of STX209 in subjects 5-11 years of age for the treatment of social function in 
FXS.  172 subjects were randomized to receive one of three dosing regimens of STX209 
or placebo.  Thirteen subjects did not complete the protocol.  Reasons for early 
discontinuation included: adverse event (10 on STX209, 1 on placebo) and withdrawal of 
consent (2 on STX209).    Safety results demonstrated that STX209 was again well 
tolerated, the most common adverse events in the study were aggression (16% vs. 17% in 
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placebo), vomiting (30% vs. 17% on placebo), anxiety (14% vs. 2% on placebo), and 
headaches (12% vs. 6% on placebo).  Efficacy results for the study were also not positive 
in this study, though the highest dose group of STX209 did approach a statistically 
significant improvement in the ABC-SA endpoint, subjects on the highest dose of 
STX209 improved by 58% but placebo-treated subjects improved by 40%, (p=0.08).  
Only two of the efficacy endpoints showed a statistically significant improvement, a 
measure of parental stress (p=0.03) and a measure of irritability, ABC-IR (p=0.03).  
These improvements were both seen only in the highest dose of STX209 as compared to 
placebo.   
 Results from the 209FX301 and 209FX302 trials conflicted with anecdotal reports 
from parents and clinicians that STX209 was beneficial.  Families participating in 
Seaside Therapeutics clinical trials were given the opportunity of participating in an 
open-label extension study where STX209 would be given over a long period of time.  
Some subjects had been participating in the extension trial for over three years and 
reported clinically meaningful benefits in social function and even vocabulary.  Retention 
for the study was high and very few subjects were discontinued for adverse events or lack 
of efficacy.  Data from the extension studies is not yet available, but it is likely that 
positive changes in efficacy measures will be observed in the open-label study.  Seaside 
Therapeutics previously completed an open-label study in ASD subjects and each of the 
efficacy measures changed during the study in a positive, and highly statistically 
significant degree.   
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Placebo Effect 
 One of the explanations for the failure of the 209FX301 and 209FX302 studies to 
show a drug effect is the possibility of a strong placebo effect.  Clinical trials of 
treatments in psychoactive drugs frequently fail to show a statistical difference from 
placebo controls.  While it is possible that some of these drugs truly were not effective, a 
larger than expected placebo effect has been cited as a frequent reason for clinical trial 
failure.   
The concept of placebo effect was first described in a study of dental pain in 1978 
(Murray & Stoessel, 2013).  Placebo effect is a phenomenon wherein patients respond to 
treatment of an inactive substance in a clinical trial or clinical practice.   Substantial 
positive responses to placebo have been noted in clinical trials in a myriad of indications.  
Pain studies frequently show a placebo effect, even in intensive settings such as cancer.  
In fatigue studies, over half of the participants in the placebo arm improved.  Placebo 
response is typically highest in indications characterized by symptoms that are subjective 
and without physiological endpoints, which is the case in most psychiatric disorders 
(Newcorn et al., 2009).  A recent meta-analysis of antidepressant trials concluded that 
68% of a given drug effect was attributable to the placebo effect alone.  The studies 
included covered a wide range of drugs and drug classes. Parkinson’s disease trials 
observed neurobiological changes to placebo of the same magnitude as those resulting 
from pharmacologic therapies (Murray & Stoessel, 2013). Placebo effects are not limited 
to drug trials, even sham surgeries have been shown to improve patient outcomes.  
Objective and physiological measurements in immune and endocrine system diseases 
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have been known to respond to placebo (Sandersen at al., 2013).  The presence of the 
placebo effect is the principal reason that control arms and double-blind studies are 
typically required to prove that a drug is safe and efficacious to enough to obtain 
regulatory approval.   Beliefs and expectations of both physicians and patients can greatly 
affect perceived benefit of a treatment, blinding both the physician and patient to the 
treatment being administered can reduce observer bias between the treatment groups.   
 There are several potential mechanisms that could cause a placebo effect.  
Regression to the mean is one possible mechanism.  Subjects with extreme or severe 
symptom measurements at baseline might improve as part of their natural history, 
regardless of treatment.    Patient characteristics could also cause a placebo effect.  
Patients with high expectations, patients with conditioned responses to treatments, or 
patients unaccustomed to the frequent visits and physician care received in a clinical trial 
might experience a benefit without a drug actually being administered.   A halo effect has 
been described in which an individual’s positive impression of a physician’s character or 
reputation results in a response bias.  The Hawthorne effect is a change in behavior 
simply due to being studied in a clinical trial and has been cited as a cause of the placebo 
effect.  The visibility of treatment could also contribute to placebo effect as beta-blockers 
administered via a pill slow the heart rate more than when they are intravenously 
administered without the patients’ knowledge (Benedetti et al., 2003).  There is a clear 
biological basis of the placebo effect since naloxone (an opioid antagonist) has been 
shown to prevent a placebo response in pain studies.  Physiologically, the placebo given 
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during trials of an anxiety medication was shown to change activity in the orbitofrontal 
and anterior cingulate cortices as well as the amygdala (Furmark, et al., 2008). 
  Placebo effect should be evenly experienced across all treatment groups in a 
randomized trial, so it is not expected to cause a substantial bias.  However, the presence 
of a strong placebo effect will “raise the bar” for a drug in a clinical trial to show a 
benefit.  If patients improve by 20% on account of placebo effect alone, the 
pharmacologic action of the drug will need to result in an additional, much larger 
improvement in order for the study to be positive.  Measurement scales might not have 
enough of a range or sensitivity to be useful in the presence of a strong placebo effect.  
For instance if a study assessment is a 10-point scale of pain severity (with 1 being no 
pain and 10 being the worst pain) and the baseline mean pain score is 8 points, the most a 
drug could improve pain is by 7 points.  If there is a substantial improvement of 6 points 
due to taking placebo, then there is little chance of showing a difference between the 
treatment groups.  If the drug was completely efficacious, then the treatment effect would 
be 7 compared to 6 for placebo.  This difference will not likely be statistically significant.  
A clinical trial will be statistically underpowered if the placebo effect is not included in 
the statistician’s estimate of planned effect size.  If there were more options in the scale 
for the subject to choose, perhaps a 100-point scale, then a truly efficacious drug would 
be less likely to receive the same score as placebo by chance alone   
Careful consideration of placebo response is critical for successful study design.  
For instance, a large retrospective review of depression trials concluded that there were 
several study design features that resulted in higher placebo response rates (Dworkin, 
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Katz, & Gitlin, 2005).  Among them were long duration trials, recruitment of patients 
before accurate diagnosis, inclusion of patients with a mild disease condition, number of 
treatment arms, studies with frequent interactions between subjects and the investigator.   
These factors can be taken into consideration when designing protocols.  Trials could be 
designed to minimize the placebo effects by shortening the trial or decreasing the number 
of treatment arms.  Study design considerations could also limit the placebo effect.  
Studies of SSRIs in autism were more likely to be positive if the protocol included a 
cross-over instead of parallel group design. The authors suggest that within-subject 
controls result in lower placebo response rates (Hollander et al., 2012).  In most cases, 
patients with a high likelihood of being a responder cannot ethically be excluded from 
clinical trials but in some cases that might be feasible and randomization groups could be 
stratified by some of these potential variables.  Similarly, there are other factors that may 
contribute to placebo response such as physician personality traits or patient attitudes.  
The traits most likely to contribute to placebo response can be identified and minimized 
by providing education on the impact of these attitudes and train clinicians to address 
them with patients before the study (Stein et al., 2006).   Personality traits could predict 
treatment response as well, as shown in a depression clinical trial in which patients who 
scored higher on measures of self-directedness or lower on harm avoidance tended to 
respond better to treatment than other groups (Kaneda at al., 2011). 
Several retrospective analyses of placebo responses have been performed in 
clinical trials of psychoactive drugs.  Individuals with anxiety, depression, or neuroticism 
have been shown to have a higher placebo response (Sandersen at al., 2013).  Patients 
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who have higher expectations for the clinical trial would likely show a higher placebo 
response as well.  Several studies of psychoactive drugs have examined baseline 
variables in order to characterize these subjects for exclusion or stratification purposes.   
A trial in anxiolytics showed that a high treatment response rate was correlated with a 
lower baseline anxiety measure score, or with disease severity
.
  
 In Huntington’s disease 
trials, patients who were not depressed were more likely to be placebo responders.  (Cuba 
et al., 2012).    In depression trials, placebo response was the highest in younger patients, 
patients with lower socioeconomic status, a shorter depressive episode duration, and a 
larger number of study sites (Rief, et al., 2009).   Similar findings were observed in 
ADHD trials in which the primary efficacy measure was a physician assessment of 
hyperactivity.  Over half of the patients randomized to placebo improved by at least 40% 
during the study.  Baseline variables that were associated with these placebo-responders 
included lack of previous stimulant exposure, minority race demography, and the 
inattentive ADHD subtype (Newcorne, et al., 2009).  Another ADHD trial analysis came 
to similar conclusions but also found that higher parental stress was an indicator of a 
more robust response, regardless of treatment (Waxmonsky et al., 2011). 
Certain patient characteristics might also be associated with likelihood of 
completing a study assessment inaccurately.  Discrepancies between informants or raters 
of childhood psychopathologies are commonly noted.  These differences can affect 
prevalence rates of different disorders and could affect diagnosis and treatment plans for 
individual families.  Discrepancies between parent and child ratings of a particular 
behavior seem to be affected by several factors including parental stress, parental 
 20 
 
psychopathology, and behavioral characteristics of the child.    Parents with high stress 
scale scores were more likely to rate their child’s behavior differently than their child 
(Stokes et al., 2013).  Some studies have shown exaggerated reports of problems in 
depressed parents or anxious parents (Trutler & Epkins, 2003).  Other studies suggest that 
parental stress might influence parents to rate less severe behaviors as requiring treatment 
(De Los Reyes & Kazdin, 2005).  If parent reports are used as a clinical trial endpoint, 
differences in the parents themselves can contribute to a greater variability in the trial, 
thus reducing the statistical power of the study or compromise the validity of the 
instrument.   
Study Objective and Rationale 
While the FMR1 mutation can be diagnosed genetically, there are known 
biomarkers for FXS severity as the level of FMRP does not correlate to symptom 
severity.  There are no validated biomarkers that could be used as an objective, 
physiological endpoint to measure treatment response.  Most of the clinical endpoints 
used in FXS studies involved assessments for specific and discrete behavioral symptoms 
such as irritability, anxiety, or sociability (Hagerman & Berry-Kravis, 2009).  Due to the 
limited cognitive ability of most FXS patients, these assessments are often completed by 
raters.  In non-institutional settings, these raters are most often parents or family 
members.  Psychological and behavioral assessments are highly subjective and variable 
and have been shown to be particularly susceptible to a placebo response.  Parent-reports, 
or other indirect assessments of a disease are also often associated with higher placebo 
response than direct or clinician-measured assessments. 
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Clinical trials are costly, especially in Phases 2 and 3, so finding ways to 
minimize the potential for placebo effect will be advantageous to drug development as a 
whole and could decrease the number of experimental trials in which patients are 
exposed.  Identifying the largest contributors to placebo effect is essential to the success 
of future clinical trials.   Studies in pervasive developmental disorders such as ASD and 
FXS are becoming more common and there is little published literature on the expected 
placebo response in these indications or methods to minimize the effect.   
The purpose of this study is to determine if any of the baseline characteristics 
measured in Seaside Therapeutics’ Phase 3 clinical trials in FXS were associated with a 
high placebo response.  If such associations exist, they can be examined in other FXS or 
ASD trials and possibly can contribute to study design in future trials.  Future trials could 
be more adequately powered and could include a subject population who are less likely to 
respond to placebo.  This would increase the probability of finding new treatments for 
these disorders and minimize the chance of type-II error in these clinical trials.  
There have been several studies examining potential predictors of placebo 
response in clinical trials of psychoactive drugs but none in FXS.  Trials in FXS have 
unique variables that could contribute to this effect.  FMR1 mutation status of the 
parent/caregiver could be one of these predictors since the mutation is associated with 
psychological and cognitive deficits.  Since FXS patients often take several other 
medications, these might have an effect as well.  The 209FX301 and 209FX302 protocols 
also measured parental stress and the parent’s perception of their child’s problem 
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behaviors – both of which could shape the parent’s expectation of the trial and thus 
predict a placebo response.  
MATERIALS AND METHODS:  
 
This study was a retrospective, post-hoc analysis of data pooled from two clinical 
trials, 209FX301 and 209FX302.  The clinical trials were both Phase 3 clinical trials in 
the United States, conducted by Seaside Therapeutics, evaluating the safety and efficacy 
of STX209 for the treatment of social function abnormalities in FXS.  Both trials were 
randomized, double-blind, placebo-controlled, parallel-group studies and were the largest 
controlled clinical trials in FXS conducted to-date.   
Subject Population 
  In total, 297 subjects were randomized in protocols 209FX301 and 209FX302.  Subjects 
were eligible for the protocols if they had a clinical diagnosis of FXS with molecular 
documentation of the FMR1 mutation (over 200 CGG repeats) and scored above average 
on a measure of social withdrawal during screening (an ABC-SW score of 8).   
Additional eligibility requirements were: being 5-11 (209FX302) or 12-50 (209FX301) 
years of age, having a stable pharmacologic treatment regimen of no more than three 
psychoactive medications, and having a parent or caregiver able to complete the study 
questionnaires.  Psychoactive medications were not permitted if used for an indication 
that was not listed on the FDA-approved labeling.  Subjects were not eligible for the 
studies if they had uncontrolled seizures, were taking anxiolytic medications (including 
SSRIs, antidepressants, propranolol, or benzodiazepines), or had any condition which 
might interfere with the conduct of the study or endanger the subjects’ well-being.  
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Informed consent was administered to the parent or legal guardian and assent was 
obtained from the subject if developmentally appropriate.  The study was approved by an 
institutional review board at each study site and was conducted according to International 
Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). 
Clinical Trial Design 
The design of each protocol was similar with the only differences being the study 
population ages and the dosing scheme.  Protocol 209FX301 was conducted in older 
subjects (ages 12-50) and utilized a flexible-dose titration in which study investigators 
used their clinical judgment to determine the optimal titrated dose (OTD) during the first 
month of the treatment period.  Available dosing regimens for study medication were 5 
mg twice daily (BID), 10 mg BID, 10 mg three-times daily (TID), and 15 mg TID.  
Investigators and subjects were blinded to whether study medication was STX209 or 
placebo.  This OTD was then maintained for the second month of the treatment period.  
Protocol 209FX302 was a blinded, fixed-dose study in a younger age group (ages 5-11); 
titration decisions and dose changes were not permitted.  Subjects were randomized to 
one of three doses of STX209 (5 mg BID, 10 mg BID, or 10 mg TID) or placebo.  The 15 
mg TID dose was not included in this age group.  Subjects in each treatment group were 
administered identical-appearing tablets three times each day.   Key details of the 
protocols and differences between them are listed in the following table: 
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Table 1: Clinical Trial Design Differences 
 
Study Detail 
Protocol Number 
209FX301 209FX302 
Ages  12-50 years 5-11 years 
Dosing Scheme Flexible Dose Titration Fixed Dosing 
Dosing Regimen 5 mg BID 
10 mg BID 
10 mg TID 
15 mg TID 
Placebo 
5 mg BID 
10 mg BID 
10 mg TID 
Placebo 
Enrollment Dates May2011-Sep2012 Aug2011-Mar2013 
Number of Visits  / Study 
Duration 
6 Visits / 20 Weeks 6 Visit / 19 Weeks 
Number of Sites 23 25 
Subjects 
Randomized/Completed 
125/119 172/159 
Randomization (n) STX209 (62) 
Placebo (63) 
STX209 5mg BID (42) 
STX209 10 mg BID (42) 
STX209 10 mg TID (43)  
Placebo (45) 
 
Subjects were evaluated during a screening period.  If eligible, subjects were 
randomized at Visit 1 and began treatment with study medication.  During the treatment 
period, subjects were titrated to their OTD (209FX301) or assigned dose (209FX302) and 
the dose was maintained until Visit 4, when study drug was slowly down-titrated.  Study 
medication was stopped and subjects were given a final physical exam at Visit 5.  A 
follow-up telephone call to collect information on adverse events and medication changes 
occurred one month after each subject’s last visit.  The overall design of the studies is 
summarized in Figure 1: 
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Figure 1: Study Design Overview 
 
 
Study Endpoints 
 The primary endpoint for the protocols was a specific subscale of the Aberrant 
Behavior Checklist-Community Edition (ABC-C).  The ABC-C is a 58-item global 
behavior checklist implemented for the measurement of drug and other treatment effects 
in individuals with intellectual disability. In its original validation, five empirically 
derived dimensions were identified: Irritability (ABC-IR), Lethargy/Social Withdrawal 
(ABC-SW), Inappropriate Speech (ABC-IS), Hyperactivity (ABC-HA), and Stereotypic 
Behavior (ABC-SB).  The subscales of the assessment do not overlap and can be 
interpreted independently. The ABC-C was originally validated on 509 institutionalized 
residents with intellectual disability (Aman et al., 1985). The ABC-IR has been used in 
previous medication studies in children with autism (McCracken et al., 2002) and in 
subjects with FXS.  Pivotal studies for aripirazole and risperidal for irritability associated 
with autism utilized the ABC-IR as a primary efficacy endpoint so the assessment has 
regulatory precedent.  FXS males were found to show significantly higher levels of 
hyperactivity, stereotypic movements, and unusual speech patterns as compared to 
controls.  The scale was also used in clinical trials for treatment of ADHD and irritability 
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symptoms.  A recent validation of the ABC-C specifically in FXS patients was 
performed, using data from over 600 subjects from multiple FXS clinics across the 
United States (Sansone et al., 2011). The factor analysis on this population identified a 
“Social Avoidance” subscale (ABC-SA) that was related to the original “Lethargy/Social 
Withdrawal” scale, but which did not include the items assessing physical lethargy. 
During this validation, the Irritability, Hyperactivity, Lethargy/Withdrawal, and 
Stereotypy subscales were modified slightly and the Inappropriate Speech subscale 
remained unchanged.  The ABC-SA subscale was the primary efficacy endpoint in the 
209FX301 and 209FX302 trials. The ABC-C was completed by the parent/caregiver.  
Secondary endpoints included the following assessments:  
 Clinical Global Impression: Improvement (CGI-I): The CGI-I is a well-validated 
measure employing a 7-point Likert scale: very much improved, much improved, 
minimally improved, no change, minimally worse, much worse, very much 
worse.  This scale is commonly used in drug studies because it allows the 
clinicians to integrate all sources of information, including the parent/caregiver 
history, observations in the clinic, and reports from other sources, into a single 
rating of improvement during treatment. For this study, the clinicians considered 
all aspects of subjects’ neurobehavioral function, including but not limited to 
internalizing problems, externalizing problems, and social engagement to 
determine how much they improved as compared to baseline; 
 Clinical Global Impression: Severity (CGI-S): The CGI-S is used to assess the 
impairment of neurobehavioral function in study subjects. The clinicians in this 
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study considered all aspects of neurobehavioral function, including but not limited 
to internalizing problems, externalizing problems, and social engagement to rate 
the overall severity of the subjects’ symptomology. The clinician’s score utilized 
the following 7-point Likert scale: normal (not at all impaired) borderline; mild; 
moderate; marked; severe; or extreme; 
 Visual Analog Scale (VAS): This is a simple assessment that captures symptom 
severity.  This methodology has been utilized in the risperidone studies in autism 
(McCracken et al., 2002; Arnold et al., 2003) and has been used in a very large 
number of studies on anxiety. The parent/caregiver was asked about severity of 
disruptive (e.g. tantrums) and anxiety-driven (e.g. hand-flapping) troublesome 
behaviors in the subject and is given examples of several such behaviors.  They 
then rated changes in severity of each target symptom on a 10 centimeter line, 
with troublesome behaviors anchored on one end with the description “worst 
ever” and on the other end with “no problem at all”. This scale was used in a prior 
study of subjects with FXS where it showed good reliability when used by parents 
and caregivers of individuals with FXS (Berry-Kravis et al., 2006); 
 Vineland Adaptive Behavior Scales, Second Edition (VABS): The VABS (Carter 
et al. 1998) is designed to assess the personal and social functioning of 
handicapped and non-handicapped persons. It is the gold standard for the 
assessment of adaptive functioning, and, with IQ testing, comprises one of two 
pillars for the assessment and diagnosis of intellectual disability. The “Survey 
Interview Form” of the VABS was administered in this study by the clinician to 
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the parent/caregiver using a semi-structured interview format.  The assessment 
included five domains:  socialization, communication, daily living skills, motor 
skills, and maladaptive behavior index.  Only the socialization domain score was 
considered a secondary endpoint in these studies.    
Exploratory efficacy endpoints included the following assessments:  
 Parenting Stress Index (PSI): The PSI provides a measure of parental stress, and is 
widely used in the assessment of family function for families with children who 
have special needs.  The short form version of the PSI was used in these studies 
and consists of 36 questions completed by the parent/caregiver.  The PSI consists 
of five subscales, one of which being parental distress, that form a total PSI score 
with higher scores being indicative of a more positive state.  The PSI was normed 
on over 2,500 parents and is a well validated estimate of the overall stress faced 
by parents (Zaidman-Zait, et al., 2010);  
 VABS communication domain and maladaptive behavior index; 
 Remaining FXS-specific ABC-C subscales: ABC-IR, ABC-HA, ABC-IS, ABC-
SB, and ABC-SW. 
Safety assessments in the protocols included physical exams, vital signs, laboratory 
tests (chemistry, hematology, urinalysis, and pregnancy tests), electrocardiograms, and a 
suicidality assessment.  Parents or caregivers (and subjects if possible) were interviewed 
at study visits and phone calls to collect information on adverse events or changes in 
concomitant medications.   
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In addition to the above-mentioned assessments, information was collected at 
baseline on the subject’s medical history, medication use, and demographic information.  
Subjects were evaluated for ASD at baseline by a clinician using the DSM-IV checklist 
section on Pervasive Development Disorders (PDD).  This section of the DSM-IV 
contained Autistic Disorder, Asperger’s Disorder, Rett Syndrome, Childhood 
Disintegrative Disorder, and PDD-Not Otherwise Specified (PDD-NOS).  The 
parent/caregiver was asked to provide the subject’s maternal FMR1 mutation status (full 
mutation, pre-mutation, or unknown) and whether the subject had previously taken 
racemic baclofen.  
Statistical Analysis 
Study data from protocols 209FX301 and 209FX302 were combined into one data set to 
provide greater statistical power, but separate secondary analyses were performed on 
each individual protocol to examine inter-study differences.  The data set included 
baseline variables and Visit 4 efficacy assessments. Subjects who did not complete the 
protocol were removed from analysis since data to determine whether or not they 
improved during the study was not available.  All statistical tests were unadjusted for 
multiplicity and performed with a 5% level of significance using the software package 
SAS
®
 version 9.3. 
 To determine a subject’s response to treatment, the analyses were first performed 
using the ABC-SA as the outcome variable.  The ABC-SA was the primary efficacy 
endpoint of the original trials, and large placebo effects were seen on this measure.  Thus 
it is critical to analyze any baseline variables that could have influenced a placebo 
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response on this variable.  In addition to the ABC-SA subscale, analyses were performed 
on the ABC-IR subscale.  This subscale was chosen since it was used in previous trials of 
autism and FXS and is a broader subscale than the ABC-SA, which only consists of four 
items on the questionnaire.  
Continuous baseline variables were tested with the ABC-SA and ABC-IR changes 
from baseline scores to determine if there were any statistically significant correlations.  
These variables included age, months from birth to diagnosis, PSI scores, VAS scores, 
and VABS scores.  During the 209FX301 and 209FX302 studies, the ABC-C and VAS 
assessments were completed twice before randomization, once at the Screening Visit and 
once at Visit 1.  The variability at baselines for these two baseline values will also be 
included as a variable as a measure of rater consistency. 
 One-way Analysis of Variance (ANOVA) and two-sample t-tests were performed 
to examine/determine/test whether there were changes in ABC-SA and ABC-IR scores 
that were related to baseline categorical variables.  These variables included gender, race, 
maternal FMR1 mutation status, CGI-S score, DSM-IV diagnosis, use of antipsychotic 
medication, use of ADHD medications, prior use of racemic baclofen, number of 
psychoactive medications used, and study protocol.   
General linear regression modeling was used to determine if there were multiple 
baseline variables that could be used to create a model to predict placebo response as 
measured by the ABC-SA or ABC-IR assessments.   All baseline variables mentioned 
above were included in the model and then variables were removed in a stepwise fashion 
to find the best-fit model.   In addition to linear regression, logistic regression modeling 
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was employed to define characteristics that could influence the odds ratio of being a 
“placebo responder”.  Several responder criteria were defined to examine whether there 
were differences in parent-rated or clinician-rated assessments.  Responders were defined 
as having more than a 25% improvement in either the ABC-SA or ABC-IR, a CGI-S 
improvement of at least 1 point, or a CGI-I score assessment of “very much improved” or 
“much improved”.  An outcome called Total Responder was created that consisted of 
subjects who met responder-criteria in all four assessments.  All baseline variables were 
also included in the logistic regression model and modifications were made in a stepwise 
fashion to find the best-fit model. 
RESULTS 
 
A total of 287 subjects were randomized and completed protocol 209FX301 (123 
subjects) or 209FX302 (164 subjects).  Most of the subjects in the entire study sample 
were male (81.5%) and Caucasian (81.9%) with a mean age of 12.5 years.  All subjects 
had a molecular diagnosis of FXS and 75.9% of those subjects were diagnosed with ASD 
or PDD-NOS at baseline.  Approximately 35% of the subjects’ mothers expressed the full 
mutation of the FMR1 gene and about 40% of the subjects’ mothers expressed the FMR1 
pre-mutation.  Roughly one-half of the subjects were taking psychoactive medications 
concurrently, with the most common medication being for ADHD.  Only a few subjects 
had previously taken racemic baclofen.  On the VAS assessment, parent/caregivers rated 
the subjects’ anxiety-driven behaviors as more problematic than disruptive behaviors.    
 Analyses for this study on placebo responder characteristics were conducted in a 
subgroup containing 106 subjects who were randomized to receive placebo instead of one 
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of the doses of STX209.  Randomization for the protocols appeared to be effective as this 
placebo subgroup did not have any substantive differences in demographics or baseline 
assessments from the overall study population or the groups receiving STX209.  Only 2 
of the 12 Asian subjects in the trial were in this placebo group, but given the small 
numbers, this was not likely a meaningful difference.  Subjects in the placebo group were 
on average 1.8 years older than the overall study population but this was due to the fact 
that the 209FX301 protocol employed a 1:1 STX209: placebo randomization scheme 
while only 25% of the 209FX302 subjects, who were younger, were randomized to 
receive placebo so there were more 209FX301 subjects in the placebo group than 
209FX302 subjects.  The average age in 209FX302 was 7.8 years and means within each 
treatment group ranged from 7.5-8.1 years, which was not significantly different between 
randomization groups in that study.  Baseline characteristics of all subjects who were 
randomized in protocols 209FX301 or 209FX302 and had follow-up data are summarized 
in Table 2.   
Table 2: Baseline Characteristics 
Baseline Characteristics of Subjects in Data Sets:  n (%) 
 All Subjects 
(n=287) 
Placebo Subjects 
(n=106) 
Gender                                          Male 
Female 
234 (81.5) 
53 (18.5) 
86 (81.1) 
20 (18.9) 
Race                                      Caucasian 
Hispanic 
Asian 
African American 
Native American 
235 (81.9) 
13 (4.5) 
12 (4.2) 
19 (6.6) 
8 (2.8) 
88 (83.0) 
5 (4.7) 
2 (1.9) 
9 (8.5) 
2 (1.9) 
DSM-IV Diagnosis                       None 
ASD 
PDD-NOS 
69 (24.1) 
180 (62.7) 
38 (13.2) 
28 (26.4) 
60 (56.6) 
18 (17.0) 
Maternal FMR1 Mutation            Full  102 (35.8) 37 (35.2) 
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Pre-Mutation 
Unknown 
112 (39.3) 
71 (24.9) 
42 (40.0) 
26 (24.8) 
Number of Psychoactive Drugs        0 
1 
2 
3 
141 (49.1) 
82 (28.6) 
49 (17.1) 
15 (5.2) 
49 (46.2) 
32 (30.2) 
19 (17.9) 
6 (5.7) 
On ADHD Medication                  Yes 
No 
121 (42.3) 
165 (57.7) 
44 (41.5) 
62 (58.5) 
On Antipsychotic Medication       Yes 
No 
51 (17.8) 
235 (82.2) 
22 (20.8) 
84 (79.2) 
Prior Use of Baclofen                     Yes 
No 
9 (3.1) 
277 (96.9) 
4 (3.8) 
102 (96.2) 
CGI-S                                        Normal 
Borderline 
Mild 
Moderate 
Marked 
Severe 
Extreme 
0 
2 (0.7) 
16 (5.6) 
98 (34.2) 
95 (33.1) 
74 (25.7) 
2 (0.7) 
0 
1 (0.9) 
5 (4.7) 
39 (36.8) 
41 (38.7) 
20 (18.9) 
0 
Baseline Characteristics of Subjects in Data Sets:  Mean [Standard Deviation] 
Age (Years) 12.5 [7.2] 14.3 [7.8] 
Age at Diagnosis (Months) 48.9 [51.7] 51.0 [43.2] 
PSI Parental Distress 
PSI Total 
41.9 [9.1] 
120.6 [56.3] 
43.9 [8.7] 
121.9 [23.2] 
FXS-ABC-C Scores 
Hyperactivity Subscale 
Irritability Subscale 
Inappropriate Speech Subscale 
Social Avoidance Subscale 
Stereotypy Subscale 
Lethargy Subscale 
 
16.9 [8.4] 
23.7 [13.8] 
6.9 [3.8] 
7.2 [3.2] 
9.4 [5.4] 
12.6 [6.3] 
 
14.7 [8.6] 
20.9 [14.3] 
6.4 [3.7] 
7.5 [3.5] 
8.8 [5.7] 
12.0 [6.7] 
VAS-Anxiety 
VAS-Disruptive Behaviors 
68.4 [22.3] 
50.6 [30.6] 
64.9 [23.7] 
43.6 [30.7] 
 Baseline efficacy variables were examined in the overall study population to 
determine if correlations existed at baseline between certain baseline variables and 
efficacy measures or if certain efficacy measures correlated well with one another.   Age 
was most strongly correlated with ABC-HA with older subjects scoring lower on the 
subscale (R
2
=0.52).  The ABC-IR correlated significantly with all baseline efficacy 
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variables except for ABC-SA and VABS-Communication.  The clinician-rated CGI-S 
seemed to parallel VABS scores with higher CGI-S ratings correlating significantly with 
better VABS communication and socialization, and lower maladaptive behavior scores.  
Overall, the baseline variables with the strongest correlation were the VAS for disruptive 
behaviors and ABC-IR (R
2
=0.76), so these assessments seem to capture similar 
information.  A correlation matrix of baseline efficacy variables in the overall study 
population (randomized to either STX209 or placebo) is presented in Table 3.  
Table 3: Baseline Efficacy Correlations 
Correlations of Baseline Continuous Variables 
All Subjects, n=287 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age n/a              
2. ABC-
IR 
-0.43 
* 
n/a             
3. ABC-
SL 
-0.08 0.46 
* 
n/a            
4. ABC-
IS 
-0.15 0.43 
* 
0.14 n/a           
5. ABC-
HA 
-0.52 
* 
0.77 
* 
0.35 
* 
0.50 
* 
n/a          
6. ABC-
SB 
-0.21 
* 
0.56 
* 
0.33 
* 
0.43 
* 
0.52 
* 
n/a         
7. ABC-
SA 
0.08 0.07 0.33 
* 
0.01 -0.04 0.13 n/a        
8. VAS-
A 
-0.37 
* 
0.51 
* 
0.30 
* 
0.20 
* 
0.40 
* 
0.20 
* 
0.19 
* 
n/a       
9. VAS-
D 
-0.37 
* 
0.76 
* 
0.31 
* 
0.29 
* 
0.61 
* 
0.41 
* 
0.02 0.54 
* 
n/a      
10. PSI-
PD 
0.04 -0.32 
* 
-0.30 
* 
-0.16 
* 
-0.23 
* 
-0.13 -0.05 -0.26 
* 
-0.32 
* 
n/a     
11. PSI-
Total 
0.06 -0.48 
* 
-0.35 
* 
-0.19 
* 
-0.33 
* 
-0.23 -0.09 -0.30 
* 
-0.44 
* 
0.84 
* 
n/a    
12. 
CGI-S 
-0.17* 0.33 
* 
0.21 
* 
0.10 0.30 
* 
0.34 
* 
0.08 0.30 
* 
0.32 
* 
-0.08 -0.14 n/a   
13. 
VABS-
Social. 
-0.30* -0.14 -0.19 
* 
-0.04 -0.06 -0.34 
* 
-0.16 
* 
0.02 -0.10 0.09 0.16 
* 
-0.38 
* 
n/a  
14. 
VABS-
Comm. 
-0.39 
* 
-0.08 -0.20 
* 
-0.01 -0.02 -0.31 
* 
-0.11 0.07 -0.04 0.06 0.11 -0.34 
* 
0.83 
* 
n/a 
15. 
VABS-
Mal. 
-0.31 
* 
0.54 
* 
0.26 
* 
0.23 
* 
0.47 
* 
0.35 
* 
0.00 0.35 
* 
0.44 
* 
-0.23 
* 
-0.33 
* 
0.26 
* 
-0.21 
* 
-0.15 
Bold = significant at p<0.05 
* = Significant at p<0.01 
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In the pooled placebo sample, 81 out of 106 subjects (76%) improved during the 
studies on the ABC-SA.   The ABC-SA score improved by an average of 2.51 points, a 
33.3% improvement.  77 subjects (73%) receiving placebo improved on the ABC-IR 
during the studies.  The ABC-IR score in this group improved an average of 5.25 points, 
a 25.1% improvement.  VAS scores in placebo subjects improved by 8.27 (19.0%) for 
disruptive behaviors and 19.54 (30.1%) for anxiety-driven behaviors.  Clinician-rated 
assessments displayed an average improvement for placebo subjects since the mean CGI-
I was 3.18 (minimally improved) and the mean CGI-S was an improvement of 0.35.   
These assessment means are also presented for each study in Table 4.  Mean values for 
placebo subjects were similar between the pooled placebo sample and the placebo 
subjects in the 209FX301 or 209FX302 studies individually. However, in the 209FX302 
study, placebo subjects were assessed by parents/caregivers as almost twice as irritable as 
the 209FX301 study and VAS scores were more severe in the 209FX302 study as well; 
these mean differences were statistically significant.   
Table 4: Baseline and Changes for Continuous Variables for Placebo Subjects 
Baseline Variable 
Score (Standard Deviation) 
Pooled Placebo 
(n=106) 
209FX301 
Placebo 
(n=62) 
209FX302 
Placebo 
(n=44) 
ABC-SA 7.52 (3.51) 7.92 (3.49) 6.95 (3.50) 
ABC-IR 20.91 (14.28) 16.05 (13.17) 27.75 (13.05) 
VAS-Anxiety 64.93 (23.70) 58.69 (24.78) 73.73 (19.11) 
VAS-Disruptive 43.62 (30.68) 33.37 (28.69) 58.07 (27.67) 
VABS-Communication 23.34 (8.94) 20.82 (9.49) 26.89 (6.72) 
VABS-Socialization 23.17 (8.95) 21.81 (10.24) 25.14 (6.29) 
VABS-Maladaptive 21.28 (8.55) 19.68 (7.79) 23.55 (9.15) 
PSI-Parental Distress 43.93 (8.71) 44.28 (8.94) 43.45 (8.45) 
PSI-Total Score 121.88 (23.20) 125.13 (23.57) 117.3 (22.12) 
CGI-S 4.7 (0.86) 4.66 (0.92) 4.75 (0.78) 
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Changes at Visit 4 Change (Standard Deviation) 
ABC-SA -2.51 (2.56) -2.42 (2.36) -2.64 (2.85) 
ABC-IR -5.25 (8.49) -5.21 (8.29) -5.32 (8.86) 
VAS-Anxiety -19.54 (25.82) -19.61 (28.79) -19.43 (21.26) 
VAS-Disruptive -8.27 (24.61) -5.98 (23.10) -11.5 (26.52) 
PSI-Parental Distress 0.56 (7.63) 0.84 (8.25) 0.16 (6.72) 
PSI-Total Score 2.33 (23.07) 3.97 (24.64) 0.02 (20.71) 
CGI-S -0.35 (0.62) -0.29 (0.55) -0.43 (0.70) 
CGI-I 3.18 (0.96) 3.08 (0.95) 3.32 (0.98) 
  
Dichotomous baseline variables were evaluated with two-sample t-tests to 
determine whether the mean ABC-SA score or ABC-IR change was different based on 
each variable.  In the pooled placebo group, none of the mean ABC-SA or ABC-IR mean 
score changes were statistically significantly different when examined by ADHD 
medication use, antipsychotic medication use, baclofen use, or gender.  The clinician-
rated CGI-S change and CGI-I changes did not differ between these variables either.   
The same analyses in the individual study placebo groups were conducted and none of 
the groups differed significantly except for antipsychotic use.  Placebo-treated subjects in 
the 209FX302 study who were taking antipsychotics improved on the CGI-S by 0.6 
points, those not on those medications improved by 0.08 (p=0.02).  Although not 
statistically significant, a similar pattern was observed on the ABC-IR (-3.6 vs. -6.0) and 
ABC-SA (-1.8 vs. -3.0) with subjects on antipsychotics showing less of a change.  
 Other categorical baseline variables were tested using one-way ANOVA to 
determine whether the mean ABC-SA change or ABC-IR change was different when 
classified by these variables.  In the pooled placebo group, there was no difference in the 
mean changes for groups with different numbers of psychoactive drugs, DSM-IV 
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diagnosis, maternal FMR1 status, or race.  CGI-S and CGI-I mean changes were 
examined as well and there were no statistically significant differences.  The tests were 
repeated in the 209FX301 and 209FX302 placebo groups separately and none of the 
differences were significant.  The only statistically significant finding was the CGI-S 
score at baseline appeared to be associated with a statistically significant difference in the 
ABC-IR.  Subjects with a rating of 6, or “severely ill”, were more likely to show a larger 
change in the ABC-IR (p=0.02).  Similar, although not statistically significant results 
were seen with ABC-SA, CGI-I, and CGI-S changes, in that more severe subjects had 
greater responses to placebo.  
Figure 2: Relationship with ABC-IR Change and CGI-S 
 
    
Continuous baseline variables were individually examined for correlations with 
the ABC-SA or ABC-IR mean score change in the pooled placebo group.  Baseline 
variables included age, time to diagnosis, VAS scores, ABC-C scores, PSI scores, CGI-S, 
and Vineland scores.  ABC-IR score changes were correlated independently with several 
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value.  Parental distress as measured by the PSI scores was significantly correlated with 
the ABC-IR change with approximately 30% of the variability in score changes being 
associated with PSI scores, parents/caregivers who reported higher stress were more 
likely to record a larger change in the ABC-IR.  Only one variable, the ABC-IR at 
baseline, was significantly correlated with the ABC-SA score change (R
2
=0.47, p=0.001), 
the rest of the variables were not significant.  Similar results were observed when 
209FX301 and 209FX302 were examined individually.  Statistically significant ABC-IR 
correlations are listed in Table 5.  
Table 5: Correlations for ABC-IR and ABC-SA 
Statistically Significant Correlations with change in 
ABC-IR 
Baseline Variable Correlation 
Coefficient 
p-value 
CGI-S -0.22 0.02 
VAS-Disruptive -0.26 0.007 
PSI-Parental Distress 0.31 0.001 
PSI-Total 0.28 0.002 
ABC-Irritability -0.35 0.002 
ABC-Lethargy -0.31 0.001 
ABC-Inappropriate Speech -0.22 0.01 
ABC-Stereotypy -0.29 0.002 
ABC-Social Avoidance -0.18 0.05 
Statistically Significant Correlations with change in 
ABC-SA 
ABC-Irritability -0.47 0.001 
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 A multiple linear regression analysis was conducted to determine if there were 
combinations of baseline variables that could predict a larger placebo response as 
measured by the ABC-SA or ABC-IR assessments.  The ABC-SA change and ABC-IR 
changes were tested in separate models.  Stepwise regression was utilized and the 
variables in the final model are presented below.  The final model predicting placebo 
response for the ABC-SA included only the baseline ABC-SA score, indicating that 19% 
of the variability was due to that score alone with higher scores at baseline predicting a 
larger change during the study.  When the studies were modeled separately, the 
209FX302 model contained additional variables including gender, antipsychotic use, 
ABC-stereotypy scores with a larger correlation coefficient of 0.52.  For the ABC-IR 
change model, the highest correlation coefficient of 0.43 was found in the 209FX301 
study with ABC-IR, gender, Vineland-communication, maternal FMR1 status, and ABC-
SL included in the model.  Subjects with FMR1 full-mutation mothers improved the most 
on the ABC-IR in the 209FX301 placebo group. 
Table 6: Multiple Linear Regression Models 
 Pooled Placebo 209FX301 Placebo 209FX302 
Placebo 
Variable Baseline Variables Included [Adjusted R
2
] 
ABC-SA ABC-SA [0.19] ABC-SA, VAS-Anxiety 
Variability [0.19] 
Gender, ABC-SA, 
ABC-SB, 
Antipsychotic Use 
[0.52] 
ABC-IR ABC-IR, PSI-Parental 
Distress, VABS-
Communication, 
Antipsychotic Use [0.22] 
ABC-IR, Gender, ABC-
SL, VABS-
Communication, 
Maternal FMR1 [0.43] 
PSI Total Score, 
ABC Variability, 
Age [0.27] 
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 To test for logistic regression, a placebo responder was defined as a subject who 
improved by 25% or greater in the ABC-SA or ABC-IR, a CGI-S improvement of 1 or 
more, or a CGI-I of “improved” or “very much improved” during the 209FX301 or 
209FX302 study.  83 (78.3%) of subjects in the pooled placebo group met this criterion 
on at least one of the scales assessed.  The assessment with the highest placebo responder 
frequency was ABC-SA, with 74 (70.0%) subjects receiving placebo improving by at 
least 25% on the scale.   Placebo responders were less frequently observed in clinician-
rated assessments such as the CGI-I and CGI-S with subjects meeting responder criteria 
in 29.3% and 26.4% of placebo treated subjects, respectively.  A total responder criterion 
of being a responder in each of the assessments was created and only a few subjects, 15 
(14.2 %) met this criterion.  The frequency of placebo responders did not differ 
significantly when examined by individual study.  Table 7 displays the number and 
frequencies of responders.  
Table 7: Placebo-Responder Frequencies 
Assessment  Pooled 
Placebo 
209FX301 
Placebo 
209FX302 
Placebo 
Number showing > 25% improvement (percentage) 
ABC-SA 74 (70.0) 44 (70.9) 30 (68.2) 
ABC-IR 54 (50.9) 37 (59.7) 17 (38.6) 
CGI-S 31 (29.3) 15 (24.2) 16 (36.4) 
CGI-I 28 (26.4) 17 (27.4) 11 (25.0) 
Total Responder 15 (14.2) 8 (12.9) 7 (15.9) 
 
A multiple logistic regression model included all baseline variables to determine 
if the likelihood of being a placebo responder could be predicted.  Stepwise regression 
was utilized and the variables in the final model are presented below.  In the pooled 
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placebo group, there were no statistically significant models for predicting response to 
ABC-SA, CGI-I, or being a total responder.  For ABC-IR response, a higher score on the 
hyperactivity subscale of the ABC-C was predictive of lower odds of being a placebo 
responder.  The CGI-S model was statistically significant and included the subject’s age, 
race and ABC-IS score.  When the studies were modeled separately, the odds of being a 
ABC-SA responder could be predicted in the 209FX302 study with gender and ADHD 
medication use remaining in the model.   As shown in Figure 3, there was a significantly 
larger chance of a subject responding to placebo if the subject was a male who is not 
taking any concurrent ADHD medications.  Also in the 209FX302 study, subjects were 
far less likely to be a responder on the ABC-IR or a total responder, if they were taking 
antipsychotic medications (Odds ratio 0.2 and 0.28, respectively.  Results and odds ratios 
in each model are presented in Table 8.   
Figure 3: 209FX302 ABC-SA Responder Predictors 
 
 
0
10
20
30
40
50
60
70
80
90
Male Female ADHD Meds No ADHD
Meds
Percentage of Responders 
 42 
 
Table 8: Logistic Regression Model Results 
Assessment 
 Pooled Placebo 
209FX301 
Placebo 209FX302 Placebo 
Variables in model (Odds Ratio, p-value) 
ABC-SA 
None Significant None Significant 
Gender (0.04,p=0.03) 
ADHD  (0.80,p=0.02) 
ABC-IR ABC-HA (0.90, 
p=0.04) 
None Significant 
Antipsychotic Med 
(0.2, p=0.02) 
CGI-S Age (0.92, p=0.04) 
Race (1.63, p=0.03) 
ABC-IS (0.87, 
p=0.003) 
None Significant None Significant 
CGI-I 
None Significant 
ABC-Hyper (0.89, 
p=0.03) 
CGI-S (3.17, 
p=0.01) 
ABC Var. (1.11, 
p=0.03) 
Total 
Responder 
None Significant None Significant 
Antipsychotic Med 
(0.28, p=0.05) 
VAS Var. (1.07, 
p=0.02) 
 
 
DISCUSSION 
 
A strong placebo response was seen in the Seaside studies as subjects receiving 
placebo improved significantly during the trial.  76% of placebo-treated subjects 
improved on the primary efficacy measure, the ABC-SA, and the average improvement 
was approximately 35% over the course of the study.  The magnitude of the improvement 
was similar to studies of other psychoactive drugs with subjective endpoints such as 
SSRI’s for the treatment of depression.   The goal of this study was to identify baseline 
variables that could predict placebo response.  Placebo response has been noted to differ 
between indications.  This has not been studied in FXS trials to-date and the Seaside 
studies were the largest controlled trials for a treatment in FXS. 
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Most of the baseline variables examined likely did not directly influence 
treatment response in placebo-treated subjects, as individually they were not associated 
with a different change in the ABC-SA, ABC-IR, or CGI measures.  One exception to 
this was that antipsychotic medication use was associated with a smaller change on the 
CGI-S.  Antipsychotic medications are commonly used in FXS and in ASD trials they 
have been shown to be effective in reducing irritability (Erickson et.al, 2011).   Since 
changes in the ABC-SA and ABC-IR scores were highly correlated in the Seaside 
studies, antipsychotic medication use may lower the likelihood of seeing an ABC-SA 
improvement in addition to affecting the ABC-IR score.  The lower placebo response in 
subjects taking these medications could be a result of parent expectations being different 
than parents of subjects not taking these medications.  Parents of children taking 
antipsychotic medications likely have more experience with drug therapies and have 
realistic expectations, since antipsychotic medications are not often used as a first-line 
therapy (Bailey et. al, 2012).  Interestingly, this difference in responses based on 
antipsychotic use was seen in the placebo group only, it was not observed when 
examined in subjects randomized to one of the STX209 groups, meaning lack of 
antipsychotic use might be a predictor of treatment response that is unique to placebo.  
Similar to the antipsychotic finding, in younger subjects (study 209FX302), there was an 
effect on the ABC-SA from gender and the use of ADHD medications, with males who 
do not take ADHD medications being more likely to respond to placebo.  There was a 
small number of females in the study so that finding will need confirmation in a larger 
sample before being considered for future studies, but the ADHD finding parallels the 
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other analyses with subjects not on the medications generally showing a larger response 
to placebo, this difference was not seen when examined in subjects randomized to 
STX209.  Approximately half of subjects in the Seaside studies were not taking any other 
psychoactive medications, a frequency lower than what has been reported in survey 
studies.  Therefore parents might not have experience with medication therapies and may 
not have a grounded and realistic set of expectations for a drug effect. 
An important finding was that more severe CGI-S scores at baseline were 
associated with larger response on the ABC-IR in the pooled placebo group.  While not 
statistically significant, similar results were seen with the ABC-SA as well.   The ABC-
IR was also correlated individually with several measures, including all other ABC-C 
subscales, VAS scales, and PSI; and in each case the more severe the behaviors in the 
assessment, the larger the average response to placebo.  This contrasts with a recent study 
in which ASD subjects with milder behavioral phenotypes were associated with a larger 
placebo response (King et al., 2013).   ASD and FXS are similar indications, but different 
placebo response predictors are often expected in different patient populations, as 
suggested by depression and ADHD analyses.  In addition to the different indication, 
there were study design differences that could have contributed to the different findings.  
The King, 2013 study utilized a clinician-rated assessment as a primary endpoint instead 
of a parent-rated assessment.  Characteristics of placebo responders could differ 
depending on the assessment rater.  Another difference between the studies is likely the 
parental stress levels.  While the King 2013 study used a different measure of parental 
stress, the baseline stress levels reported were high, whereas the mean PSI scores in the 
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209FX301 and 209FX302 were less severe.  There are numerous examples of stress 
being a determinant of the placebo response.  FXS parents in general seem to have a 
different level of stress than ASD parents.   The PSI was validated in a study of 141 
parents of children with ASD and the mean total score was 90 (Zaidman et al., 2010), 
which is more severe than the baseline PSI scores in the 209FX301 and 209FX302 
studies.   In ASD, a study of an ASD-specific parenting stress scale concluded that the 
mean stress level in parents of children with ASD were four times higher than parents of 
typically developing children and twice as high as parents of children with other 
developmental disabilities.  Factors in this stress scale that most contributed to high 
scores related to difficulties with tantrums, self-injurious behavior, and appetite/digestion.  
In addition, parents were often sleep deprived and reported difficulties managing their 
children’s behavior (Silva & Schalock., 2012).   In the Seaside studies, higher baseline 
stress levels as measured by the PSI were associated with more of a change in the ABC-
IR.  Disruptive behaviors as measured by a VAS scale correlated with ABC-IR changes 
and this would appear to be related to and a major contributor to parental stress leading to 
a conclusion that more stressed parents with more severe, disruptive children were more 
likely to respond to placebo.   
 The higher response in the parents with higher stress or more severely affected 
children could be a result of increased expectations.  There are no effective treatments for 
FXS and patients are unlikely to function independently as adults.  Seaside Therapeutics 
made great efforts to advertise the study.  In many cases, the studies were highly 
anticipated by parents eager for their children to receive a potential new treatment.   The 
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anticipation and expectations could have contributed to a placebo response, especially in 
the higher stress parents with more severe children. There is evidence that placebo 
response rates seem to be increasing faster than medication response rates in trials of 
psychoactive drugs (Flament and Bisserbe, 1997).  Patient expectation likely plays a role 
in this.  For example, the first SSRIs were approved using data from just a few studies 
since they showed a strong drug effect as compared to placebo during early trials.  
Studies of similar medications later failed to separate from placebo in their response 
rates.  This difference might be a result of patients understanding that SSRIs are effective 
and having higher expectations (Newcorn et al., 2009).     
The ABC-C scores observed in the study were much higher than the typical FXS 
population.  When the ABC-C was validated in a FXS population, a total of 459 males 
from several centers were used in the study (Sansone, 2011).  Mean ABC-IR scores for 
the 209FX301 and 209FX302 studies were almost twice as high as the scores in that 
study.  To be included in the Seaside studies, subjects needed to have social withdrawal 
behaviors worse than average so it is possible that the inflated scores are a result of 
recruiting subjects who had a more severe behavioral phenotype.  However, subjects in 
Seaside’s Phase 2 study, which enrolled subjects with severe irritability and did not show 
a strong placebo effect in the ABC-SA, had a baseline ABC-IR score of 21, which is 
comparable to the mean ABC-IR at screening in the pooled study of 209FX301 and 
209FX302.   It is therefore unlikely that the overall subjects’ behavioral phenotype was 
markedly worse than in the Phase 2 study.   Furthermore, the clinician’s rating of subject 
severity was similar to the 209FX301 and 209FX302 studies, indicating that the subject 
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behavioral severity was likely comparable.  Parental stress was not measured in the Phase 
2 study but it is possible that parental stress levels differed between the studies and could 
have contributed to the difference in the placebo effect magnitude.  Parents with higher 
stress levels at baseline were more likely to show a larger change in the ABC-IR.  
 Alternatively, the placebo response seen in this study could be a result of 
regression to the mean.  Subjects who were more severe would have higher ABC-C 
subscale scores at baseline and more of a chance of a score decreasing due to natural 
variability.   However, abnormal behaviors in FXS are pervasive and persistent 
throughout development.  It is unlikely that such a large proportion of subjects would 
improve so dramatically simply due to regression to the mean.  For clinical trials of such 
short duration, more of the subjects would be expected to remain at their baseline levels 
or just change slightly, instead of the large changes that were observed in this study.   
 The ABC-SA assessment appears to be especially susceptible to placebo effect.  
In each study, approximately 70% of subjects on placebo improved by at least 25% as 
compared to about 50% for the ABC-IR and 20% for clinician rated scales.  The ABC-
SA subscale contains only four questions so a change of just one point, perhaps due to 
chance, could represent a significant percentage improvement.   Furthermore, such a 
small scale might not have the sensitivity to detect a change in the presence of a possible 
placebo effect.  There are only four choices for each item of the ABC: the behavior is not 
a problem, a problem to a slight degree, moderately serious, or severe in degree.  This 
might not capture the range of behavioral problems in FXS – two very different behaviors 
could be given the same score since there are so few scoring categories. 
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 To the author’s knowledge, there has only been one study evaluating predictors of 
placebo effect in a developmental disorder such as autism or FXS, the King 2013 study 
referenced above.  It was a post-hoc analysis of a clinical trial of citalopram for the 
treatment of repetitive behaviors in ASD, during which 30% of subjects randomized to 
placebo improved as measured by the CGI-I.     The authors was noted that one of the 
contributors to the placebo response was likely the expectancy of the parents who 
routinely observe media coverage of autism and potential cures from behavioral, 
medication, or nutritional interventions (King et al., 2013). 
 The magnitude of the placebo response seen in the King et al. study (2013) is 
consistent to what was observed in the CGI-I assessment in this study.  Future studies in 
FXS or ASD should take this into account when determining the sample size.  The 
placebo effect size is large, but not as much as the parent-rated assessments seen in the 
209FX301 and 209FX302 studies, so parent-rated assessments should be utilized with 
caution.  There are relatively few randomized studies in ASD and several of them 
appeared to show a placebo effect.  One trial in divalproex sodium reported an almost 
negligible placebo effect of about 9%, much lower than other ASD trials and even lower 
than another trial of the same medication (Hollander et al., 2010).  Key features of this 
trial could have led to a lower placebo response.  Subjects were only included if their 
behavior on the primary endpoint (irritability) was severe, the primary endpoint was 
measured by a psychologist who was separate from the study doctor and blinded to 
adverse events; in addition the assessment was not a broad global assessment but instead 
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focused on irritability.  The treatment period of the study was also longer than most other 
trials, at 12 weeks.  
 Predictors of placebo response are sought because they could lead to 
improvements in future trials so that patients are not exposed to risk in a trial with a low 
likelihood of success.  Models to predict placebo response were conducted both with 
ABC-SA and ABC-IR scores in linear regression as well as logistic regression.  A 
predictive linear model for the ABC-SA was not determined except for the 209FX302 
study where, gender, antipsychotic medication use, and ABC-SB scores at baseline had a 
strong influence.  Otherwise, the ABC-SA score was the only influence in the model, 
indicating that there was an effect in which higher scores showed the most improvement, 
regardless of other baseline conditions.  A mean ABC-SA score change is likely not as 
informative as a responder analysis for this reason and future studies should use the 
number of subjects who improved by a set criteria rather than a mean change. A linear 
model for placebo response to the ABC-IR assessment included variables such as PSI, 
VABS scores, and antipsychotic medication usage.  A logistic model for the chance of 
improving at least 25% on the ABC-IR was only strongly predictive in the 209FX302 
study, where antipsychotic use was associated with a lower frequency of placebo 
response.  Antipsychotic medication had a similar effect in the logistic model for being a 
responder to the ABC-SA, ABC-IR, CGI-S, and CGI-I.  CGI-S improvement was 
predicted in a model considering age, race, and ABC-IS scores.   
This study would suggest that highly stressed parents, children with more severe 
behaviors, or children who are not taking any medications could be excluded from 
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clinical trials.  That is not always feasible for recruitment and the ethical implications 
should be considered.  Instead, these characteristics could be used in stratifying or 
adjusting statistical analyses.  They could also be an indicator for an investigator to take 
steps to mitigate the placebo response before the parent participates in the clinical trial.  
These study results also suggest that future clinical trials should not restrict the use of 
antipsychotic or ADHD medications as their use was associated with a lower placebo 
response.      
 Informed consent is key to clinical trial participation but extra steps can be taken 
by site staff to ensure the parents understand the probability that their child may be given 
placebo and to objectively report on any effects seen in the study.  Training of site staff is 
key as well, to temper expectations for parents.  Silva, 2012 concluded that improving 
clinical validity of behavioral measures requires multiple sources of information.  
Relying on the parent’s reports is not sufficient; an independent clinician assessment of 
the child, and perhaps reports from observers other than the parent should all be taken 
into consideration.  Psychological assessment raters often complete standardized training 
before participating in a clinical trial.  Studies in which parents or caregivers are the 
raters are not commonly standardized in this way.   There is evidence that the most 
stressed parents are completing the ABC-C with higher scores so this study suggests that 
parents should be carefully trained on completing questionnaires. 
Limitations: 
FXS is a single-gene disorder and was thought to have a relatively straightforward 
path to be translated from animal models into clinical practice.  Even in this context, the 
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condition is much more diverse and variable than anticipated.  FMRP levels or the length 
of the CGG mutation do not correlate with behavioral measures.  Also, the expression of 
the gene mutation appears to be highly variable between cells due to mosaicism and 
variable status of the methylation of the FMR1 mutation (Chonchaiya et al., 2009).  This 
could have resulted in a higher than expected variability in the 209FX301 or 209FX302 
studies.   FMRP levels and the methylation status of each subject’s mutation was not 
collected and are known to be a strong influence on behavioral phenotypes. 
FXS is a genetic disease thought to affect all races and ethnicities equally but the 
majority of patients who have been diagnosed with FXS are Caucasian and of a higher 
socioeconomic status. Bailey et al., 2003 reported survey results indicating that 
approximately 40% of families with a child with FXS had a household income over 
$100,000, far above the national average.   In the 209FX301 and 209FX302 studies, most 
of the subjects were Caucasian males thus the generalizability of the results of this study 
might be limited.   In addition, the study population in the trials might not be reflective of 
the general FXS population since so many commonly used medications (such as SSRIs) 
were part of the exclusion criteria for the study.  
Other factors in studies of psychiatric drugs that were noted to be associated with 
placebo response were not measured in the 209FX301 or 209FX302 studies and could 
not be confirmed.  For example, socioeconomic status, education, personality type, IQ, or 
psychiatric conditions (Newcorn et al., 2009).  Family income, family accommodation of 
problem behaviors, and patient insight into their own disease emerged as predictors in a 
recent obsessive-compulsive disorder study and these were not measured in the current 
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study (Garcia et al., 2010).   There was limited information available on the 
characteristics, expectations, or attitudes of the rater completing the assessments in the 
209FX301 or 209FX302 studies.  It is possible that more baseline information on the 
rater instead could have led to more variables being associated with placebo responders.   
 The study did not collect information on the parent/caregiver completing the 
assessments.  Anecdotally, reports from the site staff indicated that most of the raters in 
the study were the subjects’ mothers but this cannot be verified.  It is possible that 
mothers or fathers are more likely to respond to placebo, however, studies of stress in 
parents of children with FXS, however, did not show a significant difference in stress 
levels between mothers and fathers (McCarthy et al., 2006).  It was hypothesized that 
maternal FMR1 mutation status would be a predictive factor, however, approximately 
one-quarter of the raters did not know this information, limiting the ability to evaluate 
this thoroughly. 
 The physician relationship with the patient is often noted as a contributor to 
placebo effect.  Different clinicians will present the study in different lights and set 
patient expectations in different ways.  Stein et al., 2006 noted that depression studies in 
Europe had a higher placebo response rate than identical studies in the United States.  
They hypothesized that the difference was mainly due to European Investigators being 
comprised of general practitioners instead of specialists and that general practitioners 
likely to engage and spend more time with subjects than specialists.  This is difficult to 
measure but site variability in placebo response may be able to be detected in large 
enough clinical trials, however, most sites in the 209FX301 and 209FX302 study did not 
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enroll enough subjects from which to draw meaningful conclusions about inter-site 
differences. 
The data used in this study are sparse in comparison to large meta-analyses of 
anxiety or depression clinical trials.  The Seaside Therapeutics studies, however, 
represented the largest controlled study in FXS.  Future clinical trials in FXS will surely 
be planned which should take into account the disease-specific factors that seem to be 
associated with placebo response.   
Future Directions 
The findings in this study will need to be confirmed in future studies and in a FXS 
population that includes a study population that is more generalizable.  Future studies 
should include measures to capture rater and clinician attitudes and expectations to 
determine if they affect placebo response.  There is little evidence on whether the placebo 
effect is stable.  Longer studies will be necessary to determine if the placebo effect is 
durable.  It is also not well known if characteristics associated with placebo responders 
hold true across multiple trials or different indications.  Several studies have identified 
factors and sometimes contradict each other (Kaptchuk et al., 2008).  Natural history 
controls could be used in some settings instead of including placebo subjects.  Another 
study design that can be considered is a placebo run-in period. This has been widely used 
in depression trials in which subjects are administered placebo, in a single-blinded 
fashion, during a baseline period before the actual randomization.  If the subject shows an 
improvement, they are either excluded from the study or removed from the analysis.  A 
meta-analysis concluded that that was no discernable advantage to placebo run-in.  The 
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success of the trial or the observed effect size was not different than trials that did not 
utilize a run-in period, however, it is not known whether the same conclusion will be 
reached in FXS trials using parent/caregiver rated assessments (Lee et al., 2004).  Feltner 
(2009) used a placebo response screening scale that appeared to measure some factors 
unique to patients likely to respond to placebo.  Scales similar to this could be 
administered in small pilot studies in FXS in order to optimize the design of future 
studies.  
Future clinical studies in ASD or FXS should monitor parent expectations but also 
parental interactions with their child.  This may seem to be insurmountable, but there are 
methods to collect information that could be vital to measuring the placebo effect.  
Diaries could be completed to record time spent or activities with children, recording 
devices could provide objective measurements on voice tone or length of conversations to 
determine if this could cause variability and could contribute to a treatment effect.   
Several studies will be needed to determine if concrete and reproducible factors exist, but 
these efforts must be made in order to increase the chance of observing a treatment effect 
by drugs in future clinical trials.   In addition, endpoints other than the ABC-SA should 
be explored in FXS trials in hopes of finding endpoints that are sensitive enough to 
measure change and have a large enough range that a drug effect could still be observed 
in the presence of a large placebo effect.  
CONCLUSION: 
 
The Seaside studies were the largest controlled studies of a treatment for FXS.  
Almost 80% of subjects taking placebo improved on the study in the primary efficacy 
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variable.  Several retrospective studies of clinical trials in psychoactive medications have 
been identified baseline characteristics that may be specifically associated with a higher 
placebo response, but no such studies have been conducted in FXS.   
This study found that change on the ABC-SA assessment was not strongly 
correlated with any of the measured variables except itself, with higher scores predicting 
a larger change.  A predictive linear model for the magnitude of the ABC-SA score was 
created for placebo subjects in the 209FX302 study that indicated that gender, 
antipsychotic medication use, baseline ABC-SA, and baseline ABC-SB scores likely 
affected the change in ABC-SA score.  A predictive logistic model for the ABC-SA 
responder likelihood was only significant for the 209FX302 study, which indicated that 
gender and ADHD medication use were associated with a greater chance of being a 
placebo responder.  
The ABC-IR change was correlated with several variables including CGI-S score, 
VAS scores, parental stress, and other ABC-C subscales with more severe scores at 
baseline being associated with larger improvement on placebo.  A predictive linear model 
for the magnitude of the ABC-IR score change in the pooled placebo group indicated that 
PSI score, VABS communication score, use of antipsychotic medications, and baseline 
ABC-SA/ABC-IR scores likely affected the magnitude of the score change.   A model for 
responder likelihood for the ABC-IR included the ABC-HA subscale and antipsychotic 
medication usage.  Lastly, a model for responders to the clinician-rated CGI-S change 
included age, race, and ABC-IS scores.  Since the variables in the models are different for 
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each endpoint, future studies should consider different sets of baseline variables when 
designing study eligibility criteria or stratification variables.  
 The ABC-SA does not appear to be an effective endpoint in this patient 
population.  At baseline, 22 subjects (21%) receiving placebo reported the maximum 
score, leading to a potential ceiling effect.  The placebo effect in the Seaside studies was 
much larger on the ABC-SA than on other assessments.  The smallest placebo effect was 
seen with the Total Responder variable, indicating that a composite endpoint consisting 
of clinician assessments and parent-rated scales might be more effective.  
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